Viking Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?

Viking Therapeutics (VKTX) is set to report fourth-quarter and full-year 2024 earnings on Feb. 5, after market close. Since the company lacks a marketed drug in its portfolio, we do not expect it to record revenues. The Zacks Consensus Estimate for earnings is pegged at a loss of 27 cents per share. Estimates for 2025 loss per share have improved slightly from $1.42 to$1.41 in the past 60 days.See the Zacks Earnings Calendar to stay ahead of market-making news. Image Source: Zacks Investment ResearchVKTX’s ...